Shots:

• Theragonistics to get intellectual property rights to operate globally in the diagnostic field for selected radio radionuclide labeled PARPi along with an exclusive option to license for operating globally in the therapeutic field of selected rPARPi
• Theragonistics will develop molecular radiotherapy based on PARP inhibitor through its platform for the diagnosis and treatment of multiple cancer
• PARP inhibitors are a novel class of cancer therapies act by inhibiting Poly (ADP-Ribose) Polymerase enzyme which is used by cancerous cells to damage DNA both endogenous and as caused by treatments like chemotherapy

Click here to­ read full press release/ article

Ref: PRNewswire | Image: AstraZeneca